Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Valentin Goede

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Blood|July 17, 2009
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemiaBarbara F Eichhorst, Raymonde Busch, Stephan Stilgenbauer, et al.
Blood|May 27, 2016
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapyCarmen Diana Herling, Marion Klaumünzer, Cristiano Krings Rocha, et al.
Blood|September 9, 2022
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J Hengeveld, Michèle Y van der Klift, P Martijn Kolijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.
The New England Journal of Medicine|January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsValentin Goede, Kirsten Fischer, Raymonde Busch, et al.
Blood|October 22, 2015
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialKirsten Fischer, Jasmin Bahlo, Anna Maria Fink, et al.
Blood|April 15, 2024
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapiesPetra Langerbeins, Adam Giza, Sandra Robrecht, et al.
Haematologica|August 31, 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcriptionJennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, et al.
The New England Journal of Medicine|June 6, 2019
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsKirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic LeukemiaFlorian Simon, Rudy Ligtvoet, Sandra Robrecht, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Blood|July 17, 2009
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemiaBarbara F Eichhorst, Raymonde Busch, Stephan Stilgenbauer, et al.
Blood|May 27, 2016
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapyCarmen Diana Herling, Marion Klaumünzer, Cristiano Krings Rocha, et al.
Blood|September 9, 2022
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLLPaul J Hengeveld, Michèle Y van der Klift, P Martijn Kolijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study GroupKirsten Fischer, Paula Cramer, Raymonde Busch, et al.
The New England Journal of Medicine|January 10, 2014
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditionsValentin Goede, Kirsten Fischer, Raymonde Busch, et al.
Blood|October 22, 2015
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trialKirsten Fischer, Jasmin Bahlo, Anna Maria Fink, et al.
Blood|April 15, 2024
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapiesPetra Langerbeins, Adam Giza, Sandra Robrecht, et al.
Haematologica|August 31, 2019
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcriptionJennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, et al.
The New England Journal of Medicine|June 6, 2019
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsKirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic LeukemiaFlorian Simon, Rudy Ligtvoet, Sandra Robrecht, et al.
Pageof 6